viewOpen Orphan PLC

Open Orphan PLC: 'Rapidly scaling up and building out higher value, longer term contracts'


Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services.

She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries.

Click here to read Emma Ulker's latest update Open Orphan: Scaling Up, Leveraging Valuable Assets

Quick facts: Open Orphan PLC

Price: 25.2 GBX

Market: AIM
Market Cap: £168.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...


Market Report: FTSE gains as hopes rise of UK and France solving port chaos

FTSE 100 edged higher as France and the UK said they were near to ending the freight ban which has led to hundreds of lorries queuing outside Dover. London’s blue-chip index added 13 to 6,429 in spite of rising concerns over the new strain of COVID-19.   Mixed news for the UK economy...

3 weeks, 4 days ago

2 min read